Результаты поиска

The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia.

Transforming growth factor beta 1 (TGF-beta1) is the prototypic member of a large family of structurally related pleiotropic-secreted cytoki … entiation of leukemia cells by way of modulation of the TGF-beta1/SMAD signal pathway. For example, arsenic trioxide can promote specific degradation of the AML1/MDS1/EVI1 oncoprotein and inhibit the proliferation of leukemia cells. However, specific histone deacetylase inhibitors can interrupt the effect of histone deacetylase to alleviate EVI1-mediated suppressi …

Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia.

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarel

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.

Randomized clinical trials remain the gold standard to establish efficacy and safety of new treatments. In acute myeloid leukemia, large trials have been associated with gradual improvement in outcome over 2 decades in younger patients without major differences emerging between treatments. By contrast, in older patients, improvement has been minimal, which justifies a new approach to identifying effective treatments. Given the urgent unmet need, and with the emergence of several novel agents or combinations that are likely to be expensive, large benefits are probably required to change clinica

Adult T-cell leukemia/lymphoma and HTLV-1.

Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago. HTLV-1 infects 15 to 20 million individuals worldwide. This oncoretrovirus can be transmitted in three ways: horizontally (sexually), vertically (mother to child), and via blood transfusion. HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type. Becaus

Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.

Standard antileukemic chemotherapy induces complete remission in approximately half of patients with high-risk (HR) myelodysplastic syndrome … arnesyl transferase inhibitors (ras inhibitors), drug-antibody conjugates (Myelotarg), thalidomide, arsenic trioxide, maintenance chemotherapy with hypomethylating agents, or oral topoisomerase inhibitors along with agents modulating factors affecting growth and differentiation, should be explored to maintain remission with minimal compromise of quality of life. A …

Clinical and Molecular Profiles and Treatment Outcomes in Patients With Acute Promyelocytic Leukaemia: A Single-Centre Experience.

INTRODUCTION: Acute promyelocytic leukaemia (APL) is one of the most treatable blood cancers with a high cure rate. The reciprocal transloca … low- and high-risk groups. Twenty-nine (72.5%) patients received all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based induction chemotherapy, while 11 (27.5%) received ATRA, ATO, and daunorubicin-based induction chemotherapy. Differentiation syndrome occurred more frequently in the high-risk group than in the low-risk group (p=0.001). The most common co …

Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is one of the most severe global pandemic due to its high pathogenicity and dea … bGs, respectively. We also detected some chemicals (Valproic Acid, Cyclosporine, Copper Sulfate and arsenic trioxide) that may regulates HubGs. The disease-HubGs interaction analysis showed that our predicted HubGs are also associated with several other diseases including different types of lung diseases. Then we considered 11 HubGs mediated proteins and their reg …

ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.

BACKGROUND: Despite dramatically improved long term outcomes seen with all-trans retinoic acid therapy, and now arsenic trioxide, in acute promyelocytic leukemia (APL), early mortality remains a substantial challenge. Recent data from a single center study and the Surveillance, Epidemiology and End Results (SEER) registry report 30day mortality rates of 26% (n=18 of 70) and 17% (n=238 of 1400), respectively. Early deaths are predominately due to hemorrhage. Patients with APL invariably have abnormal laboratory hemostasis tests. The standard of practice is to prophylactically transfuse platelet…

Multiple myeloma.

High-dose therapy with stem cell transplantation (SCT) and novel targeted therapies (thalidomide, its more potent analogues, and bortezomib) … rsus dexamethasone has been completed. Studies of bortezomib combined with other drugs are ongoing. Arsenic trioxide has a number of properties showing that it targets MM cells interacting with the microenvironment. Clinical studies are ongoing as well. Other agents in MM have already been or will probably be translated soon from the bench to the bedside.

The osteogenic niche-targeted arsenic nanoparticles prevent colonization of disseminated breast tumor cells in the bone.

Up to 70% of patients with late-stage breast cancer have bone metastasis. Current treatment regimens for breast cancer bone metastasis are palliative with no therapeutic cure. Disseminated tumor cells (DTCs) colonize inside the osteogenic niches in the early stage of bone metastasis. Drug delivery into osteogenic niches to inhibit DTC colonization can prevent bone metastasis from entering its late stage and therefore cure bone metastasis. Here, we constructed a 50% DSS6 peptide conjugated nanoparticle to target the osteogenic niche. The osteogenic niche was always located at the endosteum with

Совпадение в полном тексте источника
… Arsenic trioxide also disturbed bone remodeling and reduced trabecular bone volume of the femur by decreasing osteoblast mineralization in rats 14 . However, arsenic trioxide is poisonous with cardiac toxicity, hepatotoxicity, renal failure, etc., depending on its exposure dosage in vivo . … In this report, we found that arsenic trioxide prevented DTC colonization in the osteogenic niche. However, arsenic trioxide has systemic toxicities and also disrupted the hematopoiesis in the bone marrow. …

Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy.

Vitamin C is a water-soluble vitamin introduced through the diet with anti-inflammatory, immunoregulatory, and antioxidant activities. Today, this vitamin is integrated into the treatment of many inflammatory pathologies. However, there is increasing evidence of possible use in treating autoimmune and neoplastic diseases. We reviewed the literature to delve deeper into the rationale for using vitamin C in treating this type of pathology. There is much evidence in the literature regarding the beneficial effects of vitamin C supplementation for treating autoimmune diseases such as Systemic Lupus

Совпадение в полном тексте источника
… Trioxide for Newly Diagnosed Acute Promyelocytic Leukemia | Oral arsenic Trioxide, ATRA and vitamin C | Recruiting | Interventional NCT00671697 | Decitabine, Arsenic Trioxide and vitamin C for Myelodysplastic Syndromes and Acute Myeloid Leukemia | Arsenic Trioxide Decitabine | Completed | Interventional … Trioxide, vitamin C and Bortezomib | Terminated | Interventional NCT00661544 | Arsenic Trioxide with Ascorbic Acid and Melphalan for Myeloma Patients | Arsenic Trioxide; Melphalan; vitamin C | Terminated with results | Interventional NCT00227682 | Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic …

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.

ObjectiveTwo phase I studies of darinaparsin including Japanese and Korean patients with relapsed/refractory peripheral T-cell lymphoma were performed to evaluate its safety (primary purpose), efficacy and pharmacokinetic profile (ClinicalTrials.gov: NCT01435863 and NCT01689220).MethodsPatients received intravenous darinaparsin for 5 consecutive days at 200 mg/m2/day in 4-week cycles, 300 mg/m2/day in 4-week cycles or 300 mg/m2/day in 3-week cycles.ResultsSeventeen Japanese and 6 Korean patients were enrolled and treated. Drug-related adverse events developed in 18 patients (78%). Dose-limitin

Совпадение в полном тексте источника
… Hussein MA Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10:370–4. 16. List A, Beran M, DiPersio J et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17:1499–507. 17. Hermine O, Dombret H, Poupon J et al. … Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002;16:617–22. 30. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. …

Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for over 90% of all cases. Patients with advanced-stage HCC are referred to systemic treatment. Although some advances in HCC therapy have been made in recent years, the prognosis for patients remains poor due to drug resistance, tumor relapse, and metastasis, implying that overall survival remains a challenge. Many studies have shown that tumor-initiating stem cells, also known as cancer stem cells (CSCs), play essential roles in tumorigenesis, metastasis, and treatment resistance in HCC and that future cancer

Совпадение в полном тексте источника
… A randomized, single-blind clinical trial was conducted in patients with unresectable HCC and lung metastases, in which TACE with arsenic trioxide ( n = 69) was compared with TACE with arsenic trioxide plus additional intravenous arsenic trioxide administration ( n = 70). … Furthermore, TACE with arsenic trioxide plus additional intravenous arsenic trioxide administration has a greater overall survival rate than TACE with arsenic trioxide does [ 172 ], whereas CBATO-TACE has better outcomes than TACE with arsenic trioxide/lipiodol emulsions does [ 174 , 175 ]. …

A Review of Resveratrol as a Potent Chemoprotective and Synergistic Agent in Cancer Chemotherapy.

Background: Cancer has become a major disease endangering human health around the world. Conventional chemotherapy suffers from many side effects including pain, cardiotoxicity, hepatotoxicity, and renal toxicity. This review aims to describe a natural product of resveratrol as a chemoprotective and synergistic agent in the modulation of cancer chemotherapy. Methods: The publications were identified by comprehensive searching of SciFinder, PubMed, Web of Science, and our own reference library. Search terms included combinations of "resveratrol," "cancer," "natural products," "chemotherapy," an

Совпадение в полном тексте источника
… Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest. New Drugs 20 327 – 330 . 10.1023/A:1016270206374 12201495 Wang J. Gao L. Lee Y. M. Kalesh K. A. Ong Y. S. Lim J. ( 2016 ). … Seven years’ summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide–an analysis of 242 cases. Chin. J. Hematol. 21 67 – 70 . 11876960 Zhang W. Xue J. Ge M. Yu M. Liu L. Zhang Z. ( 2013 ). Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide. …

Renaissance of Traditional Mineral Drugs in Cancer: Advanced Delivery Strategies and Bioengineering Approaches.

Traditional mineral drugs represent an underexploited reservoir of natural antitumor agents; however, their clinical translation has historically been hindered by poor bioavailability, non-specific biodistribution, and dose-limiting toxicity. This review comprehensively examines the pharmacological mechanisms and modern formulation strategies driving the renaissance of mineral-based oncology therapeutics. We highlight how mineral drugs exert potent anticancer effects through interconnected pathways, including regulated cell death (e.g., apoptosis, ferroptosis), cell-cycle arrest, and immunomod

Совпадение в полном тексте источника
… Building on TCM principles, arsenic trioxide (ATO) has been developed into highly effective arsenic-based compounds that have revolutionized the treatment of acute promyelocytic leukemia (APL) [ 9 ]. … Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol. Cancer Ther. 2002;1:851–860. 46. Rao Y., Li R., Zhang D. A drug from poison: How the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci. …

Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues.

Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the US. Despite the significant progress made in cancer treatment leading to improved prognosis and survival, ventricular arrhythmias (VA) remain a known cardiovascular complication either exacerbated or induced by the direct and indirect effects of both traditional and novel cancer treatments. Although interruption of cancer treatment because of VA is rarely required, knowledge surrounding this issue is essential for optimising the overall care of patients with cancer. The mechanisms of cancer-therapeutic-i

Совпадение в полном тексте источника
… Trioxide Arsenic trioxide, used for treatment of otherwise fatal acute promyelocytic leukaemia (APL), has been reported to cause prolongation of the QT interval (30–90% incidence) and TdP at therapeutic doses. 35 Mild prolongation of the QT interval (440–500 ms) is commonly seen and should not limit … the use of arsenic trioxide. …

Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?

Therapeutic repurposing emerged as an alternative to the traditional drug discovery and development model (DDD) of new molecular entities (NMEs). It was anticipated that by being faster, safer, and cheaper, the development would result in lower-cost drugs. As defined in this work, a repurposed cancer drug is one approved by a health regulatory authority against a non-cancer indication that then gains new approval for cancer. With this definition, only three drugs are repurposed for cancer: Bacillus Calmette-Guerin (BCG) vaccine (superficial bladder cancer, thalidomide [multiple myeloma], and p

Совпадение в полном тексте источника
… Chinese investigators published the first results on APL treatment with arsenic trioxide (ATO) in the late 1990s. A study reported complete rates with ATO as a single agent of up to 73% and 50% in newly diagnosed and relapsed APL patients [ 44 ]. … Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001;6(S2):1–2. doi: 10.1634/theoncologist.6-suppl_2-1. 44. Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qiu Q-Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. …

Arsenic Sulfide Induces Apoptosis in Myelodysplastic Neoplasm Cells Through the Suppression of ABI2.

BackgroundMyelodysplastic neoplasms (MDS) are a category of myeloid malignancies that can progress to acute myeloid leukemia (AML). Arsenic sulfide (As₂S₂) has demonstrated efficacy in the treatment of MDS. However, further investigation is required to elucidate its specific therapeutic targets.ObjectiveTo examine the influence of ABI2 on MDS and clarify the regulatory role of As₂S₂ on ABI2 within the therapeutic framework of MDS.MethodsTo explore ABI2's role in the expression and prognosis of patients with hematological malignancies, RNA interference was used to reduce ABI2 expression in SKM-

Совпадение в полном тексте источника
… This mechanism differs from that of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL). As₂O₃ contributes to the degradation of the PML-RARα fusion protein, as demonstrated in previous studies [ 16 , 25 – 27 ]. … Comparative analysis of immunological changes following Realgar and arsenic trioxide treatments in a murine model of myelodysplastic syndrome. Immunopharmacol Immunotoxicol. 2024;46:408–16. 38816179 10.1080/08923973.2024.2344158 19. …

Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.

The complex pathology of cancer development requires correspondingly complex treatments. The traditional application of individual single-target drugs fails to sufficiently treat cancer with durable therapeutic effects and tolerable adverse events. Therefore, synergistic combinations of drugs represent a promising way to enhance efficacy, overcome toxicity and optimize safety. Chinese Herbal Medicines (CHMs) have long been used as such synergistic combinations. Therefore, we summarized the synergistic combinations of CHMs used in the treatment of cancer and their roles in chemotherapy in terms

Совпадение в полном тексте источника
… Mistletoe extract and arsenic trioxide were applied more in clinical to reduce the adverse effects caused by chemotherapy (Table 3 ). … Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PLoS One. 2014;9(6):e98925. doi: 10.1371/journal.pone.0098925. 69. Gu S., Chen C., Jiang X., Zhang Z. …

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.

Classic tumor therapy, consisting of cytotoxic agents and/or targeted therapy, has not overcome therapeutic limitations like poor risk genetic parameters, genetic heterogeneity at different metastatic sites or the problem of undruggable targets. Here we summarize data and trials principally following a completely different treatment concept tackling systems biologic processes: the principle of communicative reprogramming of tumor tissues, i.e., anakoinosis (ancient greek for communication), aims at establishing novel communicative behavior of tumor tissue, the hosting organ and organism via re

Совпадение в полном тексте источника
… IMiDs, COX-2 inhibitors and arsenic trioxide represent protein-binding pro-anakoinotic drugs. … The combination arsenic trioxide and all-trans retinoic acid outcompeted ATRA plus chemotherapy for standard risk promyelocytic leukemia (APL) (Efficace et al., 2014 ). …